Understanding the incidence and outcomes of trilateral retinoblastoma
Global Survey of Trilateral Retinoblastoma: Incidence and Outcomes
This study looks at how common trilateral retinoblastoma is and how well patients survive, comparing data from different countries to see if there are differences based on income levels.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4351 (estimated) |
| Sex | All |
| Sponsor | Amsterdam UMC, location VUmc Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Amsterdam, North Holland) |
| Trial ID | NCT06367530 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the incidence and survival rates of trilateral retinoblastoma among patients diagnosed with retinoblastoma globally. It will include data from various treatment centers over a specified period, focusing on the differences in incidence between high-income and low-income countries. The study will follow a prospective cohort design, adhering to established reporting guidelines to ensure accuracy and transparency. Data will be collected on the location of the tumors, treatment received, and survival outcomes to enhance understanding of this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with retinoblastoma.
Not a fit: Patients who do not have a diagnosis of retinoblastoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved health practices and outcomes for retinoblastoma patients, particularly in low-income regions.
How similar studies have performed: Previous studies on retinoblastoma have shown success in understanding its global incidence and outcomes, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients diagnosed with retinoblastoma Exclusion Criteria: * none
Where this trial is running
Amsterdam, North Holland
- Amsterdam UMC — Amsterdam, North Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Marcus de Jong, MD PhD — Amsterdam UMC
- Study coordinator: Marcus C de Jong, MD PhD
- Email: mc.dejong@amsterdamumc.nl
- Phone: +31(0)20-4443047
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.